Risk Factors for Immune Checkpoint Inhibitor-Mediated Cardiovascular Toxicities
Yousif, Laura I; Screever, Elles M; Versluis, Daniëlle; Aboumsallem, Joseph Pierre; Nierkens, Stefan; Manintveld, Olivier C; de Boer, Rudolf A; Meijers, Wouter C
(2023) Current Oncology Reports, volume 25, issue 7, pp. 753 - 763
(Article)
Abstract
Purpose of Review: Immune checkpoint inhibitors (ICIs) have improved the field of cancer, especially in patients with advanced malignancies. Nevertheless, cardiovascular immune-related adverse events (irAEs) with high mortality and morbidity have been observed, including myocarditis, pericarditis, and vasculitis. To date, only a few clinical risk factors have been described and
... read more
are currently being investigated. Recent Findings: In this review, we address the four most prevailing risk factors for cardiovascular irAEs. ICI combination therapy is a predominant risk factor for developing ICI-mediated myocarditis. Additionally, ICI combined with other anti-cancer treatments (e.g., tyrosine kinase inhibitors, radiation, chemotherapy) seems to increase the risk of developing cardiovascular irAEs. Other risk factors include female sex, pre-existing cardiovascular disease, and specific tumors, on which we will further elaborate in this review. Summary: An a priori risk strategy to determine who is at risk to develop these cardiovascular irAEs is needed. Insights into the impact of risk factors are therefore warranted to help clinicians improve care and disease management in these patients.
show less
Download/Full Text
Keywords: Antineoplastic Agents, Immunological/adverse effects, Cardiovascular System, Female, Humans, Immune Checkpoint Inhibitors/adverse effects, Myocarditis/chemically induced, Neoplasms, Risk Factors, Pericarditis, ICI, Risk factors, Myocarditis, Vasculitis, Oncology, Journal Article, Review, Research Support, Non-U.S. Gov't
ISSN: 1523-3790
Publisher: Current Science, Inc.
Note: Publisher Copyright: © 2023, The Author(s).
(Peer reviewed)